Merck to build £1B London R&D hub for its first ex-U.S. early research center

On August 24, 2020 Merck reported that it is set to spend £1 billion ($1.31 billion) on a new unifying early research hub in England’s capital city (Press release, Merck & Co, AUG 24, 2020, View Source [SID1234563991]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new hub, which will bring together staffers from across the region to a central hub in London, will be the company’s first early-stage R&D center outside of its native U.S. The focus will be on diseases of aging, predominately in neuroscience, an area with high risk but major unmet need.

Merck had made moves to create the hub back in 2017, a year after the U.K. voted to leave the EU, and was hailed by politicians as a positive investment.

It has been somewhat delayed, given how tight space is in London (the same issues New York has with lab space) and it wanting to be in the life sciences hub by the Francis Crick biomedical research institute in north London. Merck, known as MSD in Europe, already has a major five-year neuro R&D pact with the Crick Institute.

It will be called, quite simply, the London Discovery Research Centre, and it should be up and running by 2025, with work starting late next year, should it cut through the red tape. On top of the moving scientists and staffers from its other areas into the center, it also expects to create about 120 new jobs for scientists and technicians.

In all, it expects to employ 800 people at the 25,000-square-meter site and to spend £1 billion all told on the hub.

"We currently view the U.K. as a world leader in developing science, driven by the long-term emphasis on building a strong research and development infrastructure," said David Peacock, MSD managing director for the U.K. and Ireland, speaking to the Financial Times.

Xuanzhu Bio, a Sihuan Novel Drug Subsidiary, Completes $116 Million Funding

On August 24, 2020 Sihuan Pharma reported its innovative drug subsidiary, Xuanzhu Biopharma, completed a $116 million Series A round financing from SDIC (Press release, XuanZhu Pharma, AUG 24, 2020, View Source [SID1234564024]). SDIC will own 18.6% of Xuanzhu, which is valued at $624 million. Sihuan said Xuanzhu is differentiated from other startups by having complete drug R&D capability along with the parent company’s production and commercialization support. The company has two candidates in late-stage trials: birociclib, a CDK4/6 inhibitor for advanced breast cancer and janagliflozin, an SGLT2 inhibitor for diabetes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Tentarix Biotherapeutics Launches with a $50 Million Series A Financing

On August 24, 2020 Tentarix reported that it was launched with a $50 Million Series A Financing and will leverage the ITS HuTARG core protein engineering platform to create multispecific binding molecules based on fully human antibody variable domains (Vds) (Press release, Tentarix Biotherapeutics, AUG 24, 2020, View Source [SID1234570452]). Tentarix’s mission is to develop first-in-class multispecific therapies. The Company is focused on modalities that have tissue specific function and is building a team that aims to transform biologics.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


PEEL Therapeutics Developing Cancer Drug from Plant Toxin

On August 24, 2020 PEEL Therapeutics reported that Researchers have modified a derivative of a plant toxin and linked it to a nanocarrier to create a powerful new therapeutic for childhood tumors (Press release, PEEL Therapeutics, AUG 24, 2020, View Source [SID1234564025]). The new drug and its ability to eliminate chemoresistant tumors in mice is described in a new study published in Cancer Research, a journal of the American Association for Cancer Research (AACR) (Free AACR Whitepaper). An exclusive license to develop the drug has been obtained by PEEL Therapeutics, Inc.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Scientists from Children’s Hospital of Philadelphia (CHOP) have been testing the new cancer drug for several years in the laboratory to understand its potential to treat the most aggressive of childhood tumors. The drug is a derivative of camptothecin, a toxin isolated from the bark and stem of Camptotheca acuminata (Camptotheca, Happy tree) used for thousands of years for cancer treatment in Traditional Chinese Medicine. Camptothecin poisons cancer cells and has been chemically modified to make chemotherapies like irinotecan and topotecan, drugs used today to treat childhood solid tumors, pancreatic and colorectal cancer. CHOP researchers worked with a pharmacologically enhanced camptothecin derivative called SN22. Their newly engineered drug is made from multiple SN22 molecules reversibly linked to a biocompatible carrier fully eliminated by the body after delivering its payload. In preclinical studies, this new drug accumulates in tumors 50 to 100 times more than irinotecan without causing toxicity or eliciting chemoresistance.

PEEL Therapeutics, a USA-Israeli biotech company, has licensed the new drug from CHOP to prepare an Investigational New Drug submission to the FDA. As highlighted in the paper, the engineered SN22 produced remarkably long-term remission in 80 to 100% of mice with drug-resistant tumors including neuroblastoma, Ewing sarcoma, and rhabdomyosarcoma. Many tumors completely disappeared after 4 doses and remained undetectable for over 6 months without ever returning. The CHOP study published in Cancer Research demonstrated that the drug is protected from enzymes that inactivate camptothecins and unaffected by cell transporters that pump out chemotherapies from cancer cells. Importantly for children, the paper describes that the engineered drug appears to have a better safety profile with less toxicities than irinotecan.

PEEL Therapeutics CEO and Co-Founder, Dr. Joshua Schiffman, is a pediatric oncologist and expressed excitement for PEEL’s involvement with this new drug. "At PEEL, we look for therapies inspired by evolution. The SN22 nanoparticle is the perfect example of a drug at the intersection of nature and technology. The increased delivery and decreased toxicities of this drug may offer very important advantages to patients with solid tumors, including children and adults."

PEEL Therapeutics, Inc. is an emerging biotech that delivers evolution-inspired medicines to improve patient lives. The PEEL pipeline originates from assets inspired by the evolution of elephants, plants and humans for the treatment of cancer and inflammatory diseases, including COVID-19. PEEL is supported by private investors and philanthropic charities including Closer To Cure Foundation, Animal Cancer Foundation, and Soccer for Hope Foundation. The company is located in Salt Lake City, Utah and Haifa, Israel.

Adlai Nortye Announces First Patient Dosed in Phase 1b Clinical Trial of AN0025 (EP4 Antagonist) in Combination with Merck’s KEYTRUDA® (pembrolizumab) for Advanced Solid Tumors

On August 24, 2020 Adlai Nortye Ltd. ("Adlai Nortye"), a global clinical-stage biopharmaceutical company reported that the first patient has been dosed in a phase 1b clinical trial (AN0025S0103) to evaluate AN0025, an investigational, potentially first in class oral EP4 antagonist, in combination with Merck’s KEYTRUDA (pembrolizumab) in patients with locally advanced/metastatic solid tumors (Press release, Adlai Nortye Biopharma, AUG 24, 2020, View Source [SID1234563957]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AN0025S0103 is an open-label, multicenter, phase 1b study in the U.S. and Europe to evaluate the safety and preliminary efficacy of AN0025 in combination with pembrolizumab in patients with locally advanced/metastatic tumors. It will include a dose-limiting toxicity (DLT) observation phase followed by an expansion phase. In the DLT phase, it will enroll patients with urothelial carcinoma of the bladder, or squamous or non-Squamous NSCLC, to assess safety and tolerability. This will be determined whether or not to move on to the expansion phase, which will enroll patients diagnosed with urothelial carcinoma, NSCLC, TNBC, Cervical cancer, and MSS CRC. The first patient was dosed at Huntsman Cancer Institute (HCI) at the University of Utah. In the U.S., the study is also enrolling patients from The University of Texas MD Anderson Cancer Center and The University of Virginia Cancer Center.

All enrolled patients will be treated with AN0025 and pembrolizumab until the patient experiences disease progression, unacceptable toxicity or withdraws consent, or for a maximum of 35 cycles (approximately 2 years). The dose of Pembrolizumab will remain constant at 200 mg every 3 weeks (Q3W) for each dose level of AN0025 and in each cohort.

"In preclinical studies, AN0025 combined with radiotherapy, chemoradiotherapy and with immune checkpoint inhibitors demonstrated antitumor activity in different malignancies. We are optimistic that the combination of AN0025 (EP4 Antagonist) with KEYTRUDA could have meaningful clinical benefit in patients with locally advanced/metastatic solid tumors," said Dr. Lars Birgerson, CDO and CEO of Adlai Nortye USA. "This new combination may provide a new systemic treatment option for many cancer patients, including PD-1/PD-L1 treatment refractory or relapsed patients. We hope to bring innovative cancer treatments to patients with unmet medical needs, to help patients live longer and better."

About AN0025S0103

AN0025S0103 is an open-label, multicenter, phase 1b study to evaluate the safety and preliminary efficacy of AN0025 in combination with pembrolizumab in patients with locally advanced/metastatic tumors. It will include a dose-limiting toxicity observation phase followed by an expansion phase. All enrolled patients will be treated with AN0025 and Pembrolizumab until the patient experiences disease progression, unacceptable toxicity or withdraws consent, or for a maximum of 35 cycles (approximately 2 years). The dose of pembrolizumab will remain constant at 200 mg every 3 weeks (Q3W) for each dose level of AN0025 and in each cohort.

About AN0025 (EP4 Antagonist)

AN0025 (previously E7046) is an investigational, potentially first in class oral EP4 antagonist that blocks prostaglandin E2 from binding to its subtype 4 receptor (EP4) changing the immunosuppressive character of the tumor microenvironment. Based on preliminary results, it is well tolerated in patients with solid tumors. A Phase 1b study of AN0025 in combination with the standard of care in a neoadjuvant setting for locally advanced rectal cancer showed excellent results, with nearly 40% of patients not requiring surgery or achieving a complete pathological response in the post-surgical specimen in this study.